Hanmi Pharmaceutical Reports Improved Q1 2026 Results, R&D Progress, and Shareholder Return Policy

Consolidated Q1 2026 revenue KRW 392.9 bn (YoY increase), operating profit KRW 53.6 bn (OPM 13.6%), net profit attributable to parent KRW 45.5 bn
Obesity drug 'Efpeglenatide' expected domestic launch in H2 2026 (fast-track designation, NDA submitted)
Licensed Encequidar (oral absorption enhancer) to Gilead (upfront $25M received)
Shareholder return policy: minimum total shareholder return 20% p.a. from 2025-2030 (considering buybacks, dividend increase)
R&D expense KRW 65.2 bn (16.6% of revenue), multiple pipeline assets in Ph2/3
Ongoing lawsuit: choline alfoscerate recall litigation in appeal; refund liability recognized
Total assets KRW 2.2 tn, debt ratio 50.5%, cash & equivalents KRW 140.4 bn (sound financials)